Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function
- PMID: 18381377
- DOI: 10.1136/hrt.2007.137919
Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function
Abstract
Background: Regeneration of the myocardium and improved ventricular function have been demonstrated in patients with acute myocardial infarction (MI) treated by intracoronary delivery of autologous bone marrow mononuclear cells (BMC) a few days after successful myocardial reperfusion by percutaneous coronary intervention (PCI); however, the effects of intracoronary cell infusion in chronic MI patients are still unknown.
Aims: To investigate whether intracoronary infusion of BMC into the infarct-related artery in patients with healed MI could lead to improvement in left ventricular (LV) function.
Methods: Among 47 patients with stable ischaemic heart disease due to a previous MI (13 (SD 8) months previously), 24 were randomised to intracoronary infusion of BMC (BMC group) and 23 to a saline infusion (control group) into the target vessel after successful PCI within 12 hours after chest pain occurred. LV systolic and diastolic function, infarct size and myocardial perfusion defect were assessed with the use of echocardiography, magnetic resonance imaging (MRI) or (201)Tl single-photon-emission computed tomography (SPECT) at baseline and repeated at the 6-month follow-up examination.
Results: BMC treatment did not result in a significant increase in LV ejection fraction in any of the groups by any of the methods used, and the apparent tendency of an improvement was not statistically different between the two groups. The two groups also did not differ significantly in changes of LV end-diastolic and systolic volume, infarct size or myocardial perfusion. However, there was an overall effect of BMC transfer compared with the control group with respect to early/late (E/A) (p<0.001), early diastolic velocity/late diastolic (Aa) velocity (Ea/Aa) ratio (p = 0.002) and isovolumetric relaxation time (p = 0.038) after 6 months, as evaluated by tissue Doppler echocardiography. We noted no complications associated with BMS transfer.
Conclusion: Intracoronary transfer of autologous BMC in patients with healed MI did not lead to significant improvement of cardiac systolic function, infarct size or myocardial perfusion, but did lead to improvement in diastolic function.
Similar articles
-
Impact of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: results from the BOOST trial.Eur Heart J. 2006 Apr;27(8):929-35. doi: 10.1093/eurheartj/ehi817. Epub 2006 Mar 1. Eur Heart J. 2006. PMID: 16510465 Clinical Trial.
-
Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial.Circulation. 2006 Mar 14;113(10):1287-94. doi: 10.1161/CIRCULATIONAHA.105.575118. Epub 2006 Mar 6. Circulation. 2006. PMID: 16520413 Clinical Trial.
-
Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction.N Engl J Med. 2006 Sep 21;355(12):1199-209. doi: 10.1056/NEJMoa055706. N Engl J Med. 2006. PMID: 16990383 Clinical Trial.
-
Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging.Am Heart J. 2011 Oct;162(4):671-7. doi: 10.1016/j.ahj.2011.06.019. Am Heart J. 2011. PMID: 21982659 Review.
-
Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a meta-analysis of randomised controlled clinical trials.Heart. 2013 Feb;99(4):225-32. doi: 10.1136/heartjnl-2012-302230. Epub 2012 Aug 8. Heart. 2013. PMID: 22875736 Review.
Cited by
-
A role of myocardial stiffness in cell-based cardiac repair: a hypothesis.J Cell Mol Med. 2009 Apr;13(4):660-3. doi: 10.1111/j.1582-4934.2009.00710.x. Epub 2009 Feb 20. J Cell Mol Med. 2009. PMID: 19243474 Free PMC article.
-
Global position paper on cardiovascular regenerative medicine.Eur Heart J. 2017 Sep 1;38(33):2532-2546. doi: 10.1093/eurheartj/ehx248. Eur Heart J. 2017. PMID: 28575280 Free PMC article. Review. No abstract available.
-
Cellular Therapy for Heart Failure.Curr Cardiol Rev. 2016;12(3):195-215. doi: 10.2174/1573403x12666160606121858. Curr Cardiol Rev. 2016. PMID: 27280304 Free PMC article. Review.
-
Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.Circ Res. 2013 Aug 30;113(6):810-34. doi: 10.1161/CIRCRESAHA.113.300219. Circ Res. 2013. PMID: 23989721 Free PMC article. Review.
-
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.Cochrane Database Syst Rev. 2016 Dec 24;12(12):CD007888. doi: 10.1002/14651858.CD007888.pub3. Cochrane Database Syst Rev. 2016. PMID: 28012165 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous